MedPath

BAUSCH HEALTH AMERICAS, INC.

🇺🇸United States
Ownership
Subsidiary
Employees
3.1K
Market Cap
-
Website
http://www.bauschhealth.com

The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis

Phase 3
Terminated
Conditions
Proctitis
Proctosigmoiditis
Interventions
First Posted Date
2011-05-06
Last Posted Date
2019-08-14
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
114
Registration Number
NCT01349673
Locations
🇺🇸

Gastroenterology Consultants, PA, Houston, Texas, United States

A Study of a New Drug Treatment for Acne

Phase 2
Completed
Conditions
Acne Vulgaris
Interventions
Drug: 1.2% JNJ 10229570-AAA
Drug: 2.4% JNJ 10229570-AAA
Drug: 3.6% JNJ 10229570-AAA
Other: Vehicle control
First Posted Date
2011-03-31
Last Posted Date
2019-10-16
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
431
Registration Number
NCT01326780
Locations
🇺🇸

Thomas J. Stephens & Associates, Inc., Colorado Springs, Colorado, United States

🇺🇸

Hilltop Research, Miamiville, Ohio, United States

🇺🇸

Wake Research Associates, Raleigh, North Carolina, United States

and more 14 locations

A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products

Phase 4
Completed
Conditions
Acne Vulgaris
Interventions
First Posted Date
2011-03-14
Last Posted Date
2012-02-15
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
26
Registration Number
NCT01313728
Locations
🇺🇸

Skin Study Center, Broomall, Pennsylvania, United States

A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain

Phase 3
Completed
Conditions
Opioid-Induced Constipation
Interventions
First Posted Date
2010-08-23
Last Posted Date
2019-09-06
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
804
Registration Number
NCT01186770
Locations
🇺🇸

PRA International, Raleigh, North Carolina, United States

🇺🇸

PRA, Intl., Raleigh, North Carolina, United States

Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea

Phase 2
Completed
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
First Posted Date
2010-08-09
Last Posted Date
2019-11-21
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
148
Registration Number
NCT01177410

A Study Comparing the Safety and Tolerability of Two Doses of Fipamezole in Adult Patients With Parkinson's Disease

Completed
Conditions
Parkinson's Disease
Interventions
First Posted Date
2010-06-24
Last Posted Date
2012-06-22
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
27
Registration Number
NCT01149811
Locations
🇺🇸

University of South Florida, Tampa, Florida, United States

🇺🇸

CNS Network, Inc., Torrance, California, United States

🇺🇸

Advanced Neurodiagnostic Center, Metairie, Louisiana, United States

and more 1 locations

A Study of Safety and Tolerability of Fipamezole in Adult Subjects With Parkinson's Disease Who Are Receiving Levodopa

Completed
Conditions
Parkinson's Disease
Interventions
First Posted Date
2010-06-10
Last Posted Date
2011-08-31
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
40
Registration Number
NCT01140841
Locations
🇺🇸

CNS Network, Inc., Torrance, California, United States

🇺🇸

Clinical Research Integrity Worldwide LLC, Willingboro, New Jersey, United States

🇺🇸

Quest Research Institute, Bingham Farms, Michigan, United States

and more 1 locations

A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette's Syndrome

Phase 2
Withdrawn
Conditions
Tourette's Syndrome
Interventions
First Posted Date
2010-05-28
Last Posted Date
2019-11-29
Lead Sponsor
Bausch Health Americas, Inc.
Registration Number
NCT01133353

Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome

Phase 2
Terminated
Conditions
Velo-cardio-facial Syndrome
Psychosis
Interventions
Drug: Placebo
First Posted Date
2010-05-21
Last Posted Date
2019-11-22
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
2
Registration Number
NCT01127503
Locations
🇺🇸

VCFS International Center, Syracuse, New York, United States

Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis

Phase 2
Terminated
Conditions
Psoriasis
Interventions
First Posted Date
2010-04-09
Last Posted Date
2019-07-30
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
181
Registration Number
NCT01101100
Locations
🇫🇷

Research Site, Toulouse Cedex 9, France

© Copyright 2025. All Rights Reserved by MedPath